Download Sample, Prevalence of Chronic Respiratory Disease Boost the Market Growth
Increased prevalence of chronic respiratory disease within the population due to rising levels of pollution primarily drives the market growth. Chronic respiratory disease affects the airways and other parts of the lungs. For instance, according to NIH estimation, 23% COPD cases will rise among 600 million population by 2050. However, around 47.1% new cases are expected to increase in females and double in low and middle-income countries due to poor working conditions and lack of symptom awareness. Pulmonary arterial hypertension is one of the commonly inherited COPD, common in females between 30-60 years of age. In addition, according to the report published by WHO, in November 2023, tobacco smoking is one of the leading causes of COPD, due to tobacco smoking more than 70% of cases of COPD are observed in high-income countries, and 30-40% COPD cases in middle-income countries with pollution from household being another important risk factor. In addition to smoke of cigarette, presence of dust, the overweight and physically unfit individual is more prone to the risk of developing respiratory diseases.
However, a dry powder inhaler comes as preventive care and it is a valuable option for asthma and COPD patients, by contributing a medicated target drug delivery system to lungs, with a 200-dose holding capacity, allowing use for a longer period of time and maximizing therapeutic effect with instant action. These are easy to use compared to conventional inhalers present in the market with less exacerbation effect on patients and are more environment friendly due to the absence of a chemical propeller that contains chlorofluorocarbon, making it more effective Therefore, becoming patients’ common choice and boosting the market growth.
However, a dry powder inhaler comes as preventive care and it is a valuable option for asthma and COPD patients, by contributing a medicated target drug delivery system to lungs, with a 200-dose holding capacity, allowing use for a longer period of time and maximizing therapeutic effect with instant action. These are easy to use compared to conventional inhalers present in the market with less exacerbation effect on patients and are more environment friendly due to the absence of a chemical propeller that contains chlorofluorocarbon, making it more effective Therefore, becoming patients’ common choice and boosting the market growth.
Increasing Development Demand in Dry Powder Inhaler and Government Collaboration Drives the Market Growth
Increasing demand for dry powder inhaler is attributed to the rising prevalence of long-term respiratory diseases such as cystic fibrosis, asthma, and chronic- obstructive pulmonary disease owing to market expansion. For instance, according to the report published by NIH, in 2022, 1 in 3500 individuals are affected by cystic fibrosis, one of the most common causes of death in end-stage lung disease. Therefore, due to the rising demand of more innovative inhalers, many pharmaceutical companies and industries are announcing clinical collaborations to accelerate the development of inhalers. For instance, in April 2024, Teva Pharmaceuticals Industries Ltd and Abingworth announced a collaboration to advance TEV-‘248, a dual-action combination of an inhaled corticosteroid and short-acting beta-agonist( ICS/SABA).
In this collaboration, Abingworth proposed US$150 million to Teva for research and development and it is expected to maintain SABA and underuse of inhaled corticosteroids in mild asthma patients. In addition, this market is continuously evolving with new advancements, to develop low-cost, simple and eco-friendly dry powder inhalers. For instance, in November 2023, 1nhaler a Scotland-based start-up raised US$ 2.5 million to develop single use dry powder inhaler, made up of a breathable cardboard-based membrane with dimensions as credit card, capable of delivering a specific drug to patients, and is estimated to be one of the most potential and simplest disposable inhalers at low cost, leading to increase opportunities to market players and driving the growth of market.
In this collaboration, Abingworth proposed US$150 million to Teva for research and development and it is expected to maintain SABA and underuse of inhaled corticosteroids in mild asthma patients. In addition, this market is continuously evolving with new advancements, to develop low-cost, simple and eco-friendly dry powder inhalers. For instance, in November 2023, 1nhaler a Scotland-based start-up raised US$ 2.5 million to develop single use dry powder inhaler, made up of a breathable cardboard-based membrane with dimensions as credit card, capable of delivering a specific drug to patients, and is estimated to be one of the most potential and simplest disposable inhalers at low cost, leading to increase opportunities to market players and driving the growth of market.
Recent Trends in the Dry Powder Inhaler Industry
- Increasing demand for more eco-friendly inhalers.
- Rising needs for long durability and humidity-resistance inhalers.
- Increasing demand for unit dose and multidose delivery capacity inhalers.
Explore Our Breakthrough Market Segmentation and Personalize it to Meet Your Business Needs…!
Increasing Advancement in Health Sector Hampering the Expansion of Dry Powder Market
Moisture sensitive nature of dry powder inhalers is one of the factors that hinders the market growth, as these are required to be kept in dry conditions away from humidity as there is high chance of particle clumping inside the inhaler due to the presence of saliva and water during exhalation process resulting in incapable to inhale properly and unaccountable for emergency situations. In addition, these are medicine-based inhalers, causing trouble for old-age patients in deep and quick inhaling as its delivery depends upon the amount of force applied during breathing, up to 70% of old-age patients are unable to inhale forcefully enough to active the inhaler, resulting forceful breathing may cause complications.
However, with increasing medical facilities maximum patients are adopting treatments resulting in increasing competition between market players to develop new innovative inhaler. New innovative inhalers led to rise in cost, which makes it difficult to afford in low and middle-income countries and hampers the growth of the market. Additionally, the presence of lactose in some of the dry powder inhalers increases the chances of developing allergies among lactose intolerant individuals led to a subsequent shift to standard inhalers. These factors limit the use of dry powder inhalers resulting slow market growth.
However, with increasing medical facilities maximum patients are adopting treatments resulting in increasing competition between market players to develop new innovative inhaler. New innovative inhalers led to rise in cost, which makes it difficult to afford in low and middle-income countries and hampers the growth of the market. Additionally, the presence of lactose in some of the dry powder inhalers increases the chances of developing allergies among lactose intolerant individuals led to a subsequent shift to standard inhalers. These factors limit the use of dry powder inhalers resulting slow market growth.
Growing Demand for Advanced Dry Powder Inhaler Fuels the Market Growth
The Increasing prevalence of chronic respiratory diseases among the population is driving the need for more accurate, quicker and precise inhalers in the market. For instance, in March 2023, Berry Global launched Berryhaler a dry powder inhaler to relieve COPD, asthma and other respiratory diseases, it offers ready to use dual chamber dose counter design that delivers 30 doses of double and triple customized formulations to the patient, in addition, to maintain the hygiene of the medication it is present with rotatable bidirectional mouthpiece cover, preventing overdose or under dosage of medication and resulting in accurate and safe dose.
Furthermore, according to WHO COPD is the seventh leading cause of death in the world due to poor health, with more progressive innovations and rising needs of preventive measures among COPD patients are increasing leading to an increase in the demand for new and alternative medicated inhalers in the market. It is a long-term inflammation condition that damages the lung tissue and results in breathing difficulties. For instance, in August 2023, Lupin launched the Tiotropium Dry Powder inhaler, which contains Tiotropium Bromide Inhalation Powder to treat COPD including chronic bronchitis, emphysema and more, enabling more airflow in bronchial tubes and allowing easier breathing. Inhalers are the greatest rescue supporter during emergency situations until get the system well managed.
Furthermore, according to WHO COPD is the seventh leading cause of death in the world due to poor health, with more progressive innovations and rising needs of preventive measures among COPD patients are increasing leading to an increase in the demand for new and alternative medicated inhalers in the market. It is a long-term inflammation condition that damages the lung tissue and results in breathing difficulties. For instance, in August 2023, Lupin launched the Tiotropium Dry Powder inhaler, which contains Tiotropium Bromide Inhalation Powder to treat COPD including chronic bronchitis, emphysema and more, enabling more airflow in bronchial tubes and allowing easier breathing. Inhalers are the greatest rescue supporter during emergency situations until get the system well managed.
Searching for a Country or Region Specific Report?
Unlock industry complexities with reports crafted for selected countries and regions at Reduced Cost
Rising Chronic Respiratory Disease Cases in North America Contributes to Market Expansion
North America accounted for the maximum number of respiratory disease patients in the world, Advancements in inhaler technology are attributed to rising prevalence of COPD, asthma and other chronic respiratory diseases led to increase in demand for inhalers, and projects to market growth. Advising inhalable medications for asthma and COPD are difficult even for health professionals due to the presence of wide range of devices linked with different operating principles. In contrast to other respiratory devices dry powder inhalers are valuable option for asthma and COPD patients, these come in preventive care offering targeted drug delivery systems to the lungs. With growing initiative on preventive healthcare measures, such as effective and manageable diagnosis of respiratory disease led to the launch of new dry powder inhalers aiming to improve respiratory disease. For instance, in February 2024, Catalent announced the launch of potent capsule filling capabilities for dry powder inhalers, upgrades including the largest GMP capacity for carrier-based and capsule spray-dried inhalers, in addition, it offers drum dosing technology with in-line advanced mass verification sensor technology enabling in complex powder feeding, stability and microbial control at low humidity(<10%) environment.
One of the reasons propelling the European respiratory inhalers market is the rising prevalence of respiratory disorders among the expanding population. In addition, combination therapy has proven to be more useful for asthmatic patients, that led to rise in the market for respiratory inhalers, including dry powder as they are the most effective means to administer combination medications. Asthma, COPD, pulmonary arterial hypertension, and other conditions are the major segments of the European respiratory inhalers market and many industries are expanding the manufacturing of inhaler devices to meet the rising need.
For instance, in March 2021, Vectura Group plc, announced the expansion of dry powder inhaler development and manufacturing, to support capsule inhaler devices by installing a new capsule blister packer and semi-automated device assembly machine, offering increased capacity to manufacture up to 1 million devices each year. This expansion results in increasing capabilities of single and multi-dose inhalers and rising healthcare expenditure, boosting the demand for effective inhalers. On the other hand, the Asia-Pacific is estimated to experience substantial growth in dry powder market due to rising healthcare costs in different nations such as China and India and the expanding medical infrastructure sector, which will fuel market expansion across the Dry Powder.
One of the reasons propelling the European respiratory inhalers market is the rising prevalence of respiratory disorders among the expanding population. In addition, combination therapy has proven to be more useful for asthmatic patients, that led to rise in the market for respiratory inhalers, including dry powder as they are the most effective means to administer combination medications. Asthma, COPD, pulmonary arterial hypertension, and other conditions are the major segments of the European respiratory inhalers market and many industries are expanding the manufacturing of inhaler devices to meet the rising need.
For instance, in March 2021, Vectura Group plc, announced the expansion of dry powder inhaler development and manufacturing, to support capsule inhaler devices by installing a new capsule blister packer and semi-automated device assembly machine, offering increased capacity to manufacture up to 1 million devices each year. This expansion results in increasing capabilities of single and multi-dose inhalers and rising healthcare expenditure, boosting the demand for effective inhalers. On the other hand, the Asia-Pacific is estimated to experience substantial growth in dry powder market due to rising healthcare costs in different nations such as China and India and the expanding medical infrastructure sector, which will fuel market expansion across the Dry Powder.
The report provides a detailed overview of the dry powder inhaler market insights in regions including North America, Latin America, Europe, Asia-Pacific, Oceania, and the Middle East and Africa. The country-specific assessment for dry powder inhaler market has been offered for all regional market share, along with forecasts, market scope estimates, price point assessment, and impact analysis of prominent countries and regions. Throughout this market research report, Y-o-Y growth and CAGR estimates are also incorporated for every country and region, to provide a detailed view of the crop protection chemicals market. These Y-o-Y projections on regional and country-level markets brighten the political, economic and business environment outlook, which are anticipated to have a substantial impact on the growth of the dry powder inhaler market. Some key country and region included in the crop protection chemicals market report as follows:
| North America | United States, Canada |
| Latin America | Brazil, Mexico, Argentina, Colombia, Chile, Rest of Latin America |
| Europe | Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Austria, Norway, Denmark, Finland, Ireland, Czech Republic, Rest of Europe |
| Asia Pacific | China, India, Japan, South Korea, Australia & New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific |
| Middle East and Africa | GCC Countries, South Africa, Egypt, Turkey, Morocco, Israel, Iran, Kenya, Nigeria, Rest of MEA |
Dry Powder Inhaler Market Research Report Covers In-depth Analysis on:
- Dry powder inhaler market detailed segments and segment-wise market breakdown
- Dry powder inhaler market dynamics (Recent industry trends, drivers, restraints, growth potential, opportunities in dry powder inhaler industry)
- Current, historical and forthcoming 10 years market valuation in terms of dry powder inhaler market size (US$ Mn), volume (Units), share (%), Y-o-Y growth rate, CAGR (%) analysis
- Dry powder inhaler market demand analysis
- Dry powder inhaler market pricing analysis over forecast period (by key segment and by region)
- Dry powder inhaler market regional insights with region-wise market breakdown
- Competitive analysis – key companies profiling including their market share, product offerings, and competitive strategies.
- Latest developments and innovations in dry powder inhaler market
- Regulatory landscape by key regions and key countries
- Supply chain and value chain analysis in dry powder inhaler market
- Dry powder inhaler market sales and distribution strategies
- A comprehensive overview of parent market
- A detailed viewpoint on dry powder inhaler market forecast by countries
- Mergers and acquisitions in dry powder inhaler market
- Essential information to enhance market position
- Robust research methodology
- Frequently Asked Questions -
What are the key factors driving the growth of the dry powder inhaler market?
The growth of the dry powder inhaler market is driven by increasing prevalence of respiratory diseases, technological advancements in inhaler designs, and rising awareness about the benefits of efficient drug delivery systems.
What are the major challenges faced by dry powder inhaler manufacturers?
Key challenges include stringent regulatory approvals, high development costs, and the need for enhanced patient adherence to inhaler techniques for optimal therapeutic outcomes.
How do dry powder inhalers compare to other inhaler types in terms of effectiveness?
Dry powder inhalers offer a breath-actuated mechanism, eliminating the need for propellants, which enhances their effectiveness and patient compliance compared to other inhaler types, especially metered-dose inhalers.
